: Biogen’s stock slides premarket as analysts take mixed view of Alzheimer’s disease drug approval

Biogen Inc.’s stock BIIB rose about 2% before paring those gains premarket Friday, after the U.S. Food and Drug Administration on Thursday granted full approval to Leqembi, the company’s Alzheimer’s disease treatment co-developed with Eisai Co. Ltd. ESALF. The step secures Medicare reimbursement for the first drug shown to slow the progress of the disease, rather than just treating its symptoms. The drug’s label will have a boxed warning about amyloid-related imaging abnormalities, or ARIA, which usually have no symptoms but in some rare cases cause life-threatening brain swelling, the FDA said Thursday. Oppenheimer reiterated its outperform rating on the stock and said the boxed warning may mean that greater scrutiny will be given to donanemab, a rival product from Eli Lilly & Co. LLY “We look forward to more details on donanemab efficacy and safety stratified by ApoE4 status expected at AAIC,” analysts wrote in a note, referring to the Alzheimer’s Association International Conference, scheduled for July 16 to 20. Wedbush took a more subdued tone, reiterating its neutral rating on Biogen stock. “For our part, we continue to anticipate logistics may weigh on uptake.,” analyst Laura Chico wrote in a note to clients. “No changes to our Leqembi estimates following the update. This marks an important transition period for BIIB as many of its flagship products face increasing competition, and new CEO Chris Viehbacher attempts to change both the cost structure and risk profile of the product portfolio.” Biogen’s stock was last down 1.2% but has gained 3% in the year through Thursday’s close, while the S&P 500 SPX has gained 15%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.